BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 17724152)

  • 1. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
    Ntemgwa M; Wainberg MA; Oliveira M; Moisi D; Lalonde R; Micheli V; Brenner BG
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3861-9. PubMed ID: 17724152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of HIV-1 RNAse H in resistance to nucleoside analogues.
    Roquebert B; Marcelin AG
    J Antimicrob Chemother; 2008 May; 61(5):973-5. PubMed ID: 18325896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
    J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
    Roquebert B; Wirden M; Simon A; Deval J; Katlama C; Calvez V; Marcelin AG
    J Med Virol; 2007 Mar; 79(3):207-11. PubMed ID: 17245724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K65R, TAMs and tenofovir.
    Miller MD
    AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
    Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ
    J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the RNase H primer grip domain of murine leukemia virus reverse transcriptase decrease efficiency and accuracy of plus-strand DNA transfer.
    Mbisa JL; Nikolenko GN; Pathak VK
    J Virol; 2005 Jan; 79(1):419-27. PubMed ID: 15596835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
    Cahn P; Wainberg MA
    J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
    J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
    Wirden M; Marcelin AG; Simon A; Kirstetter M; Tubiana R; Valantin MA; Paris L; Bonmarchand M; Conan F; Kalkias L; Katlama C; Calvez V
    J Med Virol; 2005 Jul; 76(3):297-301. PubMed ID: 15902696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
    García-Lerma JG; Nidtha S; Heneine W
    J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.
    Colson P; Henry M; Tivoli N; Gallais H; Gastaut JA; Moreau J; Tamalet C
    J Med Virol; 2005 Mar; 75(3):381-90. PubMed ID: 15648062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
    Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
    AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
    J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
    Parikh UM; Zelina S; Sluis-Cremer N; Mellors JW
    AIDS; 2007 Jul; 21(11):1405-14. PubMed ID: 17589186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.